WON-0003

PE

(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number : **0 555 989 A1**

(12) **EUROPEAN PATENT APPLICATION**

(21) Application number : **93300809.6**

(51) Int. Cl.[5] : **C12N 15/12,** C07K 15/00

(22) Date of filing : **04.02.93**

(30) Priority : **05.02.92 US 833835**

(43) Date of publication of application :
18.08.93 Bulletin 93/33

(84) Designated Contracting States :
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

(71) Applicant : **Bristol-Myers Squibb Company**
345 Park Avenue
New York, N.Y. 10154 (US)

(72) Inventor : **Purchio, Anthony F.**
801 33rd Avenue East
Seattle, Washington 98112 (US)
Inventor : **Neubauer, Michael G.**
2109 Second Avenue N.
Seattle, Washington 98109 (US)
Inventor : **Skonier, John E.**
6749 25th Avenue N.W.
Seattle, Washington 98117 (US)

(74) Representative : **Jones, Alan John et al**
CARPMAELS & RANSFORD 43 Bloomsbury Square
London, WC1A 2RA (GB)

(54) **TGF-beta induced gene and protein.**

(57) A new TGF-β induced gene and protein is described. Treatment of TGF-β growth arrested cells induces the production of a novel gene which encodes a 683 amino acid protein, designated BIG-H3, that contains four homologous repeat regions and which may represent a cell surface recognition molecule. This gene and protein is induced in mammalian cells, and specifically human cells, upon treatment with TGF-β.

EP 0 555 989 A1

The present invention describes a novel TGF-β induced gene, βig-h3, and the protein encoded by this induced gene, βIG-H3, produced in response to TGF-β mediated growth inhibition of specific human cell lines.

BACKGROUND OF THE INVENTION

Transforming growth factor-β1 (TGF-β1) is a multifunctional regulator of cell growth and differentiation. It is capable of causing diverse effects such as inhibition of the growth of monkey kidney cells, (Tucker, R.F., G.D. Shipley, H.L. Moses & R.W. Holley (1984) Science 226:705-707) inhibition of growth of several human cancer cell lines, (Roberts, A.B., M.A. Anzano, L.M. Wakefiled, N.S. Roches, D.F. Stern & M.B. Sporn (1985) Proc. Natl. Acad. Sci. USA 82: 119-123; Ranchalis, J.E., L.E. Gentry, Y. Agawa, S.M. Seyedin, J. McPherson, A. Purchio & D.R. Twardzik (1987) Biochem. Biophys. Res. Commun. 148:783-789) inhibition of mouse keratinocytes, (Coffey, R.J., N.J. Sipes, C.C. Bascum, R. Gravesdeal, C. Pennington, B.E. Weissman & H.L. Moses (1988) Cancer Res. 48:1596-1602; Reiss, M. & C.L. Dibble (1988 In Vitro Cell. Dev. Biol. 24:537-544) stimulation of growth of AKR-2B fibroblasts (Tucker, R.F., M.E. Olkenant, E.L. Branum & H.L. Moses (1988) Cancer Res. 43:1581-1586) and normal rat kidney fibroblasts, (Roberts, A.B., M.A. Anzano, L.C. Lamb, J.M. Smith & M.B. Sporn (1981) Proc. Natl. Acad. Sci. USA 78:5339-5343) stimulation of synthesis and secretion of fibronectin and collagen, (Ignotz, R.A. & J. Massague (1986) J. Biol. Chem. 261:4337-4345; Centrella, M., T.L. McCarthy & E. Canalis (1987) J. Biol. Chem. 262:2869-2874) induction of cartilage-specific macromolecule production in muscle mesenchymal cells, (Seyedin, S.M., A.Y. Thompson, H. Bentz, D.M. Rosen, J. McPherson, A. Contin, N.R. Siegel, G.R. Galluppi & K.A. Piez (1986) J. Biol. Chem. 261:5693-5695) and growth inhibition of T and B lymphocytes. (Kehrl, J.H., L.M. Wakefiled, A.B. Roberts, S. Jakeoview, M. Alvarez-Mon, R. Derynck, M.B. Sporn & A.S. Fauci (1986) J. Exp. Med. 163:1037-1050; Kehrl, J.H., A.B. Roberts, L.M. Wakefield, S. Jakoview, M.B. Sporn & A.S. Fauci (1987) J. Immunol. 137:3855-3860; Kasid, A., G.I. Bell & E.P. Director (1988) J. Immunol. 141:690-698; Wahl, S.M., D.A. Hunt, H.L. Wong, S. Dougherty, N. McCartney-Francis, L.M. Wahl, L. Ellingsworth, J.A. Schmidt, G. Hall, A.B. Roberts & M.B. Sporn (1988) J. Immunol. 140:3026-3032)

Recent investigations have indicated that TGF-β1 is a member of a family of closely related growth-modulating proteins including TGF-β2, (Seyedin, S.M., P.R. Segarini, D.M. Rosen, A.Y. Thompson, H. Bentz & J. Graycar (1987) J. Biol. Chem. 262:1946-1949; Cheifetz, S., J.A. Weatherbee, M.L.-S. Tsang, J.K. Anderson, J.E. Mole, R. Lucas & J. Massague (1987) Cell 48:409-415; Ikeda, T., M.M. Lioubin & H. Marquardt (1987) Biochemistry 26:2406-2410) TGF-β3, (TenDijke, P., P. Hansen, K. Iwata, C. Pieler & J.G. Foulkes (1988) Proc. Natl. Acad. Sci. USA 85:4715-4719; Derynck, R., P. Lindquist, A. Lee, D. Wen, J. Tamm, J.L. Graycar, L Rhee, A.J. Mason, D.A. Miller, R.J. Coffey, H.L. Moses & E.Y. Chen (1988) EMBO J. 7:3737-3743; Jakowlew, S.B., P.J. Dillard, P. Kondaiah, M.B. Sporn & A.B. Roberts (1988) Mol. Endocrinology. 2:747-755) TGF-β4, (Jakowlew, S.B., P.J. Dillard, M.B. Sporn & A.B. Roberts (1988) Mol. Endocrinology. 2:1186-1195) Mullerian inhibitory substance, (Cate, R.L., R.J. Mattaliano, C. Hession, R. Tizard, N.M. Faber, A. Cheung, E.G. Ninfa, A.Z. Frey, D.J. Dash, E.P. Chow, R.A. Fisher, J.M. Bertonis, G. Torres, B.P. Wallner, K.L. Ramachandran, R.C. Ragin, T.F. Manganaro, D.T. Maclaughlin & P.K, Donahoe (1986) Cell 45:685-698) and the inhibins. (Mason, A. J., J.S. Hayflick, N. Ling, F. Esch, N. Ueno, S.-Y. Ying, R. Guillemin, H. Niall & P.H. Seeburg (1985) Nature 318:659-663)

TGF-β1 is a 24-kDa protein consisting of two identical disulfide-bonded 12 kD subunits. (Assoian, R.K., A. Komoriya, C.A. Meyers, D.M. Miller & M.B. Sporn (1983) J. Biol. Chem. 258:7155-7160; Frolik, C.A., L.L. Dart, C.A. Meyers, D.M. Miller & M.B. Sporn (1983) Proc. Natl. Acad. Sci. USA 80:3676-3680; Frolik, C.A., L.M. Wakefiled, D.M. Smith & M.B. Sporn (1984) J. Biol. Chem. 259:10995-11000) Analysis of cDNA clones coding for human, (Derynck, R., J.A. Jarrett, E.Y. Chem, D.H. Eaton, J.R. Bell, R.K. Assoian, A.B. Roberts, M.B. Sporn & D.V. Goeddel (1985) Nature 316:701-705) murine, (Derynck, R., J.A. Jarrett, E.Y. Chem, & D.V. Goeddel (1986) J. Biol. Chem. 261:4377-4379) and simian (Sharples, K., G.D. Plowman, T.M. Rose, D.R. Twardzik & A.F. Purchio (1987) DNA 6:239-244) TGF-β1 indicates that this protein is synthesized as a larger 390 amino acid pre-pro-TGF-β1 precursor; the carboxyl terminal 112 amino acid portion is then proteolytically cleaved to yield the TGF-β1 monomer.

The simian TGF-β1 cDNA clone has been expressed to high levels in Chinese hamster ovary (CHO) cells. Analysis of the proteins secreted by these cells using site-specific antipeptide antibodies, peptide mapping, and protein sequencing revealed that both mature and precursor forms of TGF-β were produced and were held together, in part, by a complex array of disulfide bonds. (Gentry, L.E., N.R. Webb, J. Lim, A.M. Brunner, J.E. Ranchalis, D.R. Twardzik, M.N. Lioubin, H. Marquardt & A.F. Purchio (1987) Mol. Cell Biol. 7:3418-3427; Gentry, L.E., M.N. Lioubin, A.F. Purchio & H. Marquardt (1988) Mol. Cell. Biol. 8:4162-4168) Upon purification away from the 24kD mature rTGF-β1, the 90 to 110 kD precursor complex was found to consist of three species: pro-TGFβ1, the pro-region of the TGF-β1 precursor, and mature TGF-β1. (Gentry, L.E., N.R. Webb, J. Lim, A.M. Brunner, J.E. Ranchalis, D.R. Twardzik, M.N. Lioubin, H. Marquardt & A.F. Purchio (1987) Mol. Cell Biol.

7:3418-3427; Gentry, L.E., M.N. Lioubin, A.F. Purchio & H. Marquardt (1988) Mol. Cell. Biol. 8:4162-4168) Detection of optimal biological activity required acidification before analysis, indicating that rTGF-β1 was secreted in a latent form.

The pro-region of the TGF-β1 precursor was found to be glycosylated at three sites (Asn 82, Asn 136, and Asn 176) and the first two of these (Asn 82 and Asn 136) contain mannose-6-phosphate residues. (Brunner, A.M., L.E. Gentry, J.A. Cooper & A.F. Purchio (1988) Mol. Cell Biol. 8:2229-2232; Purchio, A.F., J.A. Cooper, A.M. Brunner, M.N. Lioubin, L.E. Gentry, K.S. Kovacina, R.A. Roth & H. Marquardt (1988) J. Biol. Chem. 263:14211-14215) In addition, the rTGF-β1 precursor is capable of binding to the mannose-6-phosphate receptor and may imply a mechanism for delivery to lysomes where proteolytic processing can occur. (Kornfeld, S. (1986) J. Clin. Invest. 77:1-6)

TGF-β2 is also a 24-kD homodimer of identical disulfide-bonded 112 amino acid subunits (Marquardt, H., M.N. Lioubin & T. Ikeda (1987) J. Biol. Chem. 262:12127-12131). Analysis of cDNA clones coding for human (Madisen, L., N.R. Webb, T.M. Rose, H. Marquardt, T. Ikeda, D. Twardzik, S. Seyedin & A.F. Purchio (1988) DNA 7:1-8; DeMartin, R., B. Plaendler, R. Hoefer-Warbinek, H. Gaugitsch, M. Wrann, H. Schlusener, J.M. Seifert, S. Bodmer, A. Fontana & E. Hoefer. EMBO J. 6:3673-3677) and simian (Hanks, S.K., R. Armour, J.H. Baldwin, F. Maldonado, J. Spiess & R.W. Holley (1988) Proc. Natl. Acad. Sci. USA 85:79-82) TGF-β2 showed that it, too, is synthesized as a larger precursor protein. The mature regions of TGF-β1 and TGF-β2 show 70 % homology, whereas 30 % homology occurs in the pro-region of the precursor. In the case of simian and human TGF-β2 precursor proteins differing by a 28 amino acid insertion in the pro-region; mRNA coding for these two proteins is thought to occur via differential splicing (Webb, N.R., L. Madisen, T.M. Rose & A.F. Purchio (1988) DNA 7:493-497).

The effects of TGF-β are thought to be mediated by the binding to specific receptors present on the surface of most cells (Massague, J. et al. (1985) J. Biol. Chem. 260:2636-2645; Segarini, P.R. et al. (1989) Mol. Endocrino. 3:261-272; Tucker, R.F., et al. (1984) Proc. Natl. Acad. Sci. USA 81:6757-6761; Wakefield, L.M., et al. (1987) J. Cell Biol. 105:965-975). Chemical crosslinking of [^{125}I]-labeled TGF-β to cell surface components has identified three receptor size classes having molecule weights of 53-70 kDA (type I receptor), 80-120 kDa (type II receptor) and 250-350 kDa (type III receptor). The type I and II receptors have been implicated in signal transduction (Boyd, F.T. et al. (1989) J. Biol. Chem. 264:2272-2278; Laiho, M., et al. (1990) J. Biol. Chem. 265:18518-18524) while the type III receptor has been suggested to act as a storage protein (Segarini, P.R. et al. (1989) Mol. Endocrino. 3:261-272). Little is known concerning signal transduction mechanisms which occur after receptor-ligand interaction.

The pleiotrophic effects of TGF-β may be due to its ability to affect the transcription of other genes. TGF-β has been shown to induce *fos*, *myc* and *sis* in AKR-2B cells (Leof, E.B., et al. (1986) Proc. Natl. Acad. Sci. USA 83:1453-1458):1453-1458) enhance expression of c-*jun* B in A549 cells (Pertovaara, L., et al. (1989) Molecular and Cellular Biology 9:1255-1264), increase the mRNA for matrix proteins (Penttinen, R.P., et al. (1988) Proc. Natl. Acad. Sci. USA 85: 1105-1110), IL-6 (Elias, J.A., et al. (1991) J. Immunol. 146:3437-3446) and EGF-receptors (Thompson, K.L. et al. (1988) J. Biol. Chem. 263:19519-19528) and decrease expression of PDGF receptor a subunits (Battegay, E. J., et al. (1990) Cell 63: 515-524). It alters the pattern of integrin expression in osteosarcoma cells (Heino, J., et al. (1989) J. Biol. Chem. 264:21806-21813) and decreases the express of c-*myc* in keratinocytes (Coffey, R.J. et al. (1988b) Cancer Res. 48:1596-1602). TGF-β induces expression of Il-1β, TNF-α, PDGF and bFGF in human peripheral blood monocytes (McCartney-Francis, N., et al. (1991) DNA and Cell Biology 10:293-300).

SUMMARY OF THE INVENTION

The present invention is directed to a novel protein and gene induced by transforming growth factor beta (TGF-β) in mammalian cells.

In order to identify novel genes that encode protein products which might be involved in mediating some of the effects of TGF-β, a cDNA library was constructed from mRNA isolated from mammalian cells, such as human lung adenocarcinoma cells, which had been growth arrested by exposure to TGF-β. Several clones were isolated. One clone, termed TGF-β induced gene-h3 (βig-h3) encoded a novel protein, βIG-H3, containing 683 amino acid residues.

In the present invention a TGF-β induced protein is produced in growth arrested mammalian cells and preferably contains about 683 amino acid residues. The TGF-β induced protein preferably contains four homologous repeat regions of approximately 140 amino acids each and has an Arg-Gly-Asp sequence near its carboxy terminus. Treatment of mammalian cells such as human adenocarcinoma cells and embryonic mesenchymal cells with TGF-β produces a 10 to 20 fold increase in these cells of a 3.4 kb RNA construct that encodes a protein of this invention.

The present invention is further directed to the protein βIG-H3 which contains a 683 amino acid residue sequence corresponding to Sequence ID Number 2 and which contains an Arg-Gly-Asp at residues 642-644 of the amino acid sequence depicted in FIGURE 5. βIG-H3 contains four homologous repeat regions that share at least 16% homology with each other.

The present invention is also directed to a nucleotide sequence that encodes a gene whose expression is strongly induced by TGF-β. The nucleotide sequence of the present invention can induce the production of a RNA transcript of about 3.4 kb, and preferably encodes the expression of βIG-H3.

DESCRIPTION OF THE FIGURES

In the drawings:

FIGURE 1 illustrates the expression βIG-H3 in A549 cells after treatment with TGF-β1 and TGF-β2. Confluent dishes of A549 cells grown in DMEM + 10% FBS were split 1:10. Twenty hours later, they were treated with 20 ng/ml rTGF-β1 (A and C) or rTGF-β2 [D] for 72 hours. Total RNA was isolated and 25 μg was fractionated on an agarose-formaldehyde gel and analyzed by Northern blotting using [^{32}P]-labeled βIG-H3 probe. Lane 1, RNA from untreated cells; lane 2, RNA from TGF-β treated cells. Exposure time for A and D, 10 hours; exposure time for C, 3 days. Panel B is a photograph of the gel in panel A stain with methylene blue. Bands were quantitated using a Molecular Dynamics Phosphoimager.

FIGURE 2 illustrates the time course for induction of βIG-H3 mRNA by TGF-β1. Confluent dishes of A549 cells were split 1:10. Twenty hours later, they were treated with TGF-β1 (20 ng/ml) for 6 hours (lane 2), 24 hours (lane 3), 48 hours (lane 4), 72 hours (lane 5), or 96 hours (lane 6): RNA was isolated and hybridized to [^{32}-P]-labeled βig-h3 probe. Lane 1 contains RNA from untreated cells.

FIGURE 3 illustrates the removal of TGF-β1 from the culture media of A549 cells leads to a decrease in synthesis of βig-h3 RNA. A549 cells were treated with TGF-β1 (20 ng/ml) for 3 days. Cells were then washed and grown in complete medium without TGF-β1 for 24 hours (lane 2), 48 hours (lane 3), 72 hours (lane 4) or 3 weeks (lane 5). RNA was extracted and analyzed by Northern blotting using [^{32}-P]-labeled βig-h3 probe. Lane 1 contains RNA from A549 cells treated for 3 days with TGF-β1.

FIGURE 4 illustrates the determination of βig-h3 mRNA half-life. A549 cells were treated with TGF-β (20 ng/ml) for 48 hours. Actinomycin D (10 ng/ml) was then added and RNA was extracted at the indicated times and analyzed by Northern blotting with [^{32}-P]-labeled βig-h3 probe. Bands were quantitated using a Molecular Dynamics Phosphoimager and are plotted as percentage of cpm remaining in the 3.4 kb βig-h3 RNA band. O——O, untreated cells; O——O, TGF-β treated cells.

FIGURE 5 illustrates the nucleotide and deduced amino acid sequence of βIG-H3. Sequencing was performed as described (Sanger, F., et al. (1977) Proc. Natl. Acad. Sci. USA 74:5463-5467) and two dependent clones were sequenced for each region. The signal sequence is overlined and arrows mark predicted cleavage sites: the RGD sequence is boxed. Repeats 1 through 4 are bracketed and a polyadenylation signal at nucleotide 2625 is indicated (horizontal bracket).

FIGURE 6A illustrates the 4 homologous domains of βIG-H3 compared with the third repeats from drosophila fasciclin-I (DrF-3), grasshopper fasciclin-I (GrF-3), and the carboxy terminal half of the Mycobacterium bovus protein Mpb70. Boxed amino acids are identical to at least 2 others at that same position.

FIGURE 6B illustrates the 4 repeats of βIG-H3 directly compared. Boxed amino acids are identical with at least 1 other at that same position. Multiple alignments were generated using the program Pileup of UW/GCG software.

DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention is directed to a nucleotide sequence and a protein that is induced in mammalian cells in response to TGF-β.

The arrest of the growth of specific mammalian cells, such as human lung adenocarcinoma cells, by treatment with TGF-β resulted in the increased induction of a novel gene product. TGF-β refers to a family of highly-related dimeric proteins which are known to regulate the growth and differentiation of many cell type. As used herein, the term "TGF-β" refers to any member of the family of transforming growth factor beta which include TGF-β1, TGF-β2, TGF-β3, TGF-β4, TGF-β5 as well as the TGF-β1/β2 hybrid molecules, designated 5-β.

TGF-β is known to regulate the transcription of several genes, such as the genes encoding c-myc, c-sis, and the platelet-derived growth factor receptor. In the present invention, an attempt was made to identify novel genes whose protein products could be involved in mediating some of the pleiotropic effects of TGF-β. As a result of the present invention a new gene product has been identified in mammalian cells that have been growth arrested by TGF-β.

All amino acid residues identified herein are in the natural of L-configuration. In keeping with standard polypeptide nomenclature, abbreviations for amino acid residues are as follows:

AMINO ACID	SYMBOL 3-Letter	SYMBOL 1-Letter
Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic acid	Asp	D
Aspartic acid or Asparagine	Asx	B
Cysteine	Cys	C
Glutamine	Gln	Q
Glutamic acid	Glu	E
Glycine	Gly	G
Glutamic acid or Glutamine	Glx	Z
Histidine	His	H
Isoleucine	Ile	I
Leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
Tryptophan	Trp	W
Tyrosine	Tyr	Y
Valine	Val	V

In the present invention, a substantially pure protein is isolated. This protein is produced in a mammalian cell in response to contacting the cells with sufficient TGF-β to arrest the growth of the mammalian cell.

As used herein the term "mammalian cell" refers to cells derived from a mammal, or mammalian tumor, including human cells such as human lung adenocarcinoma cells, human embryonic palatal mesenchymal cells and human prostatic adenocarcinoma cells.

As used herein the term "induced" refers to the stimulation, promotion and/or amplification of transcription or translation in a target cell. In a preferred embodiment of the present invention either RNA or protein production can be induced by TGF- β in a mammalian cell.

In a particularly preferred embodiment, TGF- β induced protein of the present invention has an amino acid residue sequence of about 683 amino acid residues.

When mammalian cells, such as human lung adenocarcinoma are treated with TGF-β1, growth inhibition of the cells resulted. A cDNA library was constructed and screened in order to isolate a clone which displayed increased hybridization to a cDNA probe prepared from TGF-β1 treated cells. One clone was isolated and designated βig-h3.

It was found that TGF-β1 and TGF-β2 each induced βig-h3 in cells. The induction was reversible and resulted from an increase in transcription. Analysis of the induced βig-h3 DNA revealed an open reading frame that encoded a novel 683 amino acid protein, βIG-H3, which contained a secretory leader signal sequence and an Arg-Gly-Asp sequence. βIG-H3 contained four internal repeat regions. These repeat regions display limited homology with short regions of grasshopper and drosophila fasciclin-I and Mpb70 from mycobacterium bovus. Fasciclin-I is a surface recognition glycoprotein expressed on subsets of axon bundles in insect embryos. Fasciclin-I contains four homologous 150 amino acid domains and has approximately 40% homology between grasshopper and drosophila (Zimm et al. (1988) Cell 53:577-583). It is thus considered in this inven-

tion that βig-h3 may encode a novel surface recognition protein. As such, and as proposed for fasciclin-I, the four homologous repeats could suggest a tetrameric structure with two binding sites, one at each intrachain dimer. This structure allows one βIG-H3 molecule to bind to a surface protein on two different cells. Additionally, the Arg-Gly-Asp sequence in βIG-H3, which is not present in fasciclin-I, may allow for interactions with various integrins.

βIG-H3 represents a new gene product induced by TGF-β and may illumimate the pleiotropic effects of TGF-β as, partly, being due to its ability to regulate gene transcription. It has recently been shown that growth inhibition by TGF-β is linked to inhibition of phosphorylation of pRB, the product of the retinoblastoma susceptibility gene (Pietenpol, et al. (1990) Cell 61:777-75; Laiko et al. (1990) Cell 62:175-185). If βIG-H3 is involved in cell surface recognition, it may participate in cell-cell communication and in the transmission of intracellular signals that are involved in negative growth control.

The present invention is further described by the following Examples which are intended to be illustrative and not limiting.

EXAMPLE 1

Identification of βig-h3 and Induction By TGF-β

Several human cell lines were cultured and used in these studies. A549 and H2981 (both human lung adenocarcinoma) cells, and the human breast carcinoma cell lines (MDA 453, MDA468 and 293) were grown in Dulbecco's Modified Eagle's medium (DMEM) plus 10 % fetal bovine serum (FBS). The human breast carcinoma line MCF-7 was grown in DMEM + 10% FBS containing 60 ng/ml of insulin, and human prostatic adenocarcinoma cells (PC-3) were grown in a mixture of DMEM and Hank's F-12 medium (1:1) containing 10% FBS. Several routine and general methological procedures were utilized and are described in the articles cited herein, all of which are incorporated by reference.

Confluent dishes of A549 cells were split 1:10. Twenty hours later, they were treated with 20 ng/ml recombinant TGF-β1 in complete medium for 72 hours. This resulted in an 80-90 % inhibition of DNA synthesis. A549 cells which were not treated with TGF-β1 were used as controls. Poly (A) containing RNA was extracted and a cDNA library was constructed in λ gt-10 by the method described in Webb et al. (1987) DNA 6:71-78, which is incorporated herein by reference. Duplicate filters were screened with [^{32}-P]-labeled cDNA from treated and untreated cells. Plaques showing increased hybridization to the treated probe were purified through the tertiary stage and the cDNA inserts were subcloned into pEMBL, as described in Dente et al. (1983) Nucleic Acids Res. 11: 1645-1654. Several clones were isolated and one clone, pβig-h3a, was chosen for further study.

DNA sequence analysis of pβig-h3 detects a major transcript of 3.4 kb which is induced about 10-fold in A549 cells after a 72 hours with TGF-β1 (FIGURE 1A). A longer exposure of FIGURE 1A demonstrates that the βig-h3 transcript can be detected at low levels in untreated cells (FIGURE 1C) βig-h3 is also induced by TGF-β2, as shown in FIGURE 1D, and thus appears to be a TGF-β induced gene. A time course induction is presented in FIGURE 2 and indicated that maximal stimulation of βig-h3 by TGF-β1 in A549 cells occurred after 48 hours of TGF-β1 treatment (a 20-fold increase above untreated cells).

Noticeable morphological changes of A459 cells occur upon TGF-β treatment. The cells appear larger, more spread out and assume a flattened morphology. These phenotypic changes are reversed upon removal of TGF-β and regrowth of the cells in complete media.

Removal of TGF-β1 from the culture medium resulted in a decrease in the expression of βig-h3 to the levels found in untreated cells (FIGURE 3) This finding is consistent with the reversible growth inhibition of those cells.

Total RNA was extracted from both untreated cells and from cells treated with TGF-β, as described above. The RNA was fractionated on a 1 %, agarose-formaldehyde gel, according to the method of Lehrach et al. (1977) Biochemistry 16:4743-4751, transferred to a nylon membrane (Hybond N, Amersham) and hybridized to [^{32}-P]-labeled probe, according to the method described in Madisen et al. (1988) DNA 7:1-8. The bands were quantitated using a Molecular Dynamics Phosphoimager.

The increase in βig-h3 RNA could be due to either an increase in transcription or an increase in half-life. The half-life of the βig-h3 transcripts was determined in untreated and TGF-β1 treated A549 cells. The results shown in Figure 4, illustrate that the half-life for βig-h3 RNA in untreated cells was about 5 hours, and is only slightly increased to 7 hours in TGF-β1 treated, transcriptionally inhibited (actinomycin D-treated) cells. The major increase in βig-h3 RNA thus appears to be due to an increase in transcription, rather than an increase in half-life. As shown in Figure 2, the kinetics of βig-h3 message accumulation implies a half-life of 7-11 hours, which is the same range observed in the actinomycin D studies. This suggests that message stability is not grossly altered by actinomycin D in these studies.

Several human normal and cancer cell lines were examined for induction of βig-h3. TGF-β1 treatment of HEPM (human embryonic palatal mesenchymal) cells, H2981 cells resulted in an increase in βig-h3 mRNA. βig-h3 message was not induced by TGF-β1 in 293 cells nor in the breast cancer cell lines MCF-7, MDA453 or MDA468. The fact that βig-h3 is not induced in all cell types is not a unique finding, as the induction of other genes by TGF-β have been known to vary in different cell lines. For example, c-myc is reported to be stimulated in AKR-2B fibroblasts (Leof et al. (1986) Proc. Natl. Acad. Sci. USA 83:1453-1458), but down regulated in keratonicytes (Coffey et al. (1988) Cancer Res. 48:1596-1602).

EXAMPLE 2

Sequence Analysis

DNA sequence analysis was performed by the method of Sanger et al. (1977) Proc. Natl. Acad. Sci. USA 74:5463-54679.

Nucleotide sequence analysis of pβig-h3a revealed that it contained a partial open reading frame. The cDNA library was therefore rescreened with [^{32}-P]-labeled βig-h3a probe until several overlapping clones encoding the entire open reading frame were obtained. The nucleotide and deduced amino acid sequence of βIG-H3 is shown in FIGURE 5 and is described in Sequence I.D. Number 1 and 2. The cDNA contains a single open reading frame encoding a 683 amino acid protein, βIG-H3. βIG-H3 contains an amino terminal signal peptide and an RGD sequence located at the carboxy terminus (residues 642-644). This motif has previously been shown to serve as a ligand recognition sequence for several integrins (Ruoslahti, E. (1989) J. Biol Chem. 264:13369-13371). There are no predicted sites of N-linked glycosylation. A polyadenylation signal is present at nucleotide residue 2624.

A Tfasta search of the Genebank and EMBL databases with the βig-h3 open reading frame indicated that the protein was unique. Short regions with homology to grasshopper and drosophila fasciclin-I and Mpb70 from Mycobacterium bovus were identified. FIGURE 6/A shows multiple alignments of regions from these proteins.

Upon dot matrix analysis of βIG-H3 four homologous domains of approximately 140 amino acids were revealed. A comparison of these repeats is shown in FIGURE 6B and illustrate interdomain homologies ranging from 31 % (between domains 2 and 4) to 16% (between domains 1 and 3), with domain 3 the most divergent. These interdomain homologies are similar to those found in fasciclin-I, wherein repeat 2 appears to be the most divergent. The domains of βIG-H3 and fasciclin-I share 3 highly conserved amino acid stretches. One stretch contains 9 of 10 amino acids conserved at the amino end (T X F A P S N E A W). A second stretch has 6 of 8 amino acids conserved about 30 residues from the amino end (R X I L N X H I); and a third region near the carboxy end has 12 of 16 amino acids conserved (A T N G V V H X I D X V L X X P). These comparisons are illustrated in FIGURE 6A.

Mpb70 in the major secreted protein from Mycobacterium bovus, the causal agent of bovine tuberculosis. Mpb70 occurs as a dimer of a 163 amino acid monomer with 33 % homology to the βIG-H3 domains in the carboxy terminal 97 amino acids. The amino terminal 66 amino acids carry mycobacterium specific epitopes (Redford et al. (1990) J. of Gen. Microbiol. 136:265-272).

The foregoing description and Examples are intended as illustrative of the present invention, but not as limiting. Numerous variations and modifications may be effected without departing from the true spirit and scope of the present invention.

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT:

(A) NAME: BRISTOL-MYERS SQUIBB COMPANY

(B) STREET: 345 PARK AVENUE

(C) CITY: NEW YORK

(D) STATE: NEW YORK

(E) COUNTRY: USA

(F) POSTAL CODE: 10154

(ii) TITLE OF INVENTION: TGF-BETA INDUCED GENE AND PROTEIN

(iii) NUMBER OF SEQUENCES: 2

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(v) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2691 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: LUNG

(G) CELL TYPE: ADENOCARCINOMA

(H) CELL LINE: A549

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GCTTGCCCGT CGGTCGCTAG CTCGCTCGGT GCGCGTCGTC CCGCTCCATG GCGCTCTTCG 60

TGCGGCTGCT GGCTCTCGCC CTGGCTCTGG CCCTGGGCCC CGCCGCGACC CTGGCGGGTC 120

CCGCCAAGTC GCCCTACCAG CTGGTGCTGC AGCACAGCAG GCTCCGGGGC CGCCAGCACG 180

GCCCCAACGT GTGTGCTGTG CAGAAGGTTA TTGGCACTAA TAGGAAGTAC TTCACCAACT 240

GCAAGCAGTG GTACCAAAGG AAAATCTGTG GCAAATCAAC AGTCATCAGC TACGAGTGCT 300

GTCCTGGATA TGAAAAGGTC CCTGGGGAGA AGGGCTGTCC AGCAGCCCTA CCACTCTCAA 360

ACCTTTACGA GACCCTGGGA GTCGTTGGAT CCACCACCAC TCAGCTGTAC ACGGACCGCA 420

CGGAGAAGCT GAGGCCTGAG ATGGAGGGGC CCGGCAGCTT CACCATCTTC GCCCCTAGCA 480

ACGAGGCCTG GGCCTCCTTG CCAGCTGAAG TGCTGGACTC CCTGGTCAGC AATGTCAACA 540

TTGAGCTGCT CAATGCCCTC CGCTACCATA TGGTGGGCAG GCGAGTCCTG ACTGATGAGC 600

TGAAACACGG CATGACCCTC ACCTCTATGT ACCAGAATTC CAACATCCAG ATCCACCACT 660

ATCCTAATGG GATTGTAACT GTGAACTGTG CCCGGCTCCT GAAAGCCGAC CACCATGCAA 720

CCAACGGGGT GGTGCACCTC ATCGATAAGG TCATCTCCAC CATCACCAAC AACATCCAGC 780

AGATCATTGA GATCGAGGAC ACCTTTGAGA CCCTTCGGGC TGCTGTGGCT GCATCAGGGC 840

TCAACACGAT GCTTGAAGGT AACGGCCAGT ACACGCTTTT GGCCCCGACC AATGAGGCCT 900

TCGAGAAGAT CCCTAGTGAG ACTTTGAACC GTATCCTGGG CGACCCAGAA GCCCTGAGAG 960

ACCTGCTGAA CAACCACATC TTGAAGTCAG CTATGTGTGC TGAAGCCATC GTTGCGGGGC 1020

TGTCTGTAGA GACCCTGGAG GGCACGACAC TGGAGGTGGG CTGCAGCGGG GACATGCTCA 1080

CTATCAACGG GAAGGCGATC ATCTCCAATA AAGACATCCT AGCCACCAAC GGGGTGATCC 1140

ACTACATTGA TGAGCTACTC ATCCCAGACT CAGCCAAGAC ACTATTTGAA TTGGCTGCAG 1200

AGTCTGATGT GTCCACAGCC ATTGACCTTT TCAGACAAGC CGGCCTCGGC AATCATCTCT 1260

CTGGAAGTGA GCGGTTGACC CTCCTGGCTC CCCTGAATTC TGTATTCAAA GATGGAACCC 1320

CTCCAATTGA TGCCCATACA AGGAATTTGC TTCGGAACCA CATAATTAAA GACCAGCTGG 1380

CCTCTAAGTA TCTGTACCAT GGACAGACCC TGGAAACTCT GGGCGGCAAA AAACTGAGAG 1440

TTTTTGTTTA TCGTAATAGC CTCTGCATTG AGAACAGCTG CATCGCGGCC CACGACAAGA 1500

GGGGGAGGTA CGGGACCCTG TTCACGATGG ACCGGGTGCT GACCCCCCCA ATGGGGACTG 1560

TCATGGATGT CCTGAAGGGA GACAATCGCT TTAGCATGCT GGTAGCTGCC ATCCAGTCTG 1620

CAGGACTGAC GGAGACCCTC AACCGGGAAG GAGTCTACAC AGTCTTTGCT CCCACAAATG 1680

AAGCCTTCCG AGCCCTGCCA CCAAGAGAAC GGAGCAGACT CTTGGGAGAT GCCAAGGAAC 1740

TTGCCAACAT CCTGAAATAC CACATTGGTG ATGAAATCCT GGTTAGCGGA GGCATCGGGG 1800

CCCTGGTGCG GCTAAAGTCT CTCCAAGGTG ACAAGCTGGA AGTCAGCTTG AAAAACAATG 1860

TGGTGAGTGT CAACAAGGAG CCTGTTGCCG AGCCTGACAT CATGGCCACA AATGGCGTGG 1920

TCCATGTCAT CACCAATGTT CTGCAGCCTC CAGCCAACAG ACCTCAGGAA AGAGGGGATG 1980

```
AACTTGCAGA CTCTGCGCTT GAGATCTTCA AACAAGCATC AGCGTTTTCC AGGGCTTCCC    2040
AGAGGTCTGT GCGACTAGCC CCTGTCTATC AAAAGTTATT AGAGAGGATG AAGCATTAGC    2100
TTGAAGCACT ACAGGAGGAA TGCACCACGG CAGCTCTCCG CCAATTTCTC TCAGATTTCC    2160
ACAGAGACTG TTTGAATGTT TTCAAAACCA AGTATCACAC TTTAATGTAC ATGGGCCGCA    2220
CCATAATGAG ATGTGAGCCT TGTGCATGTG GGGGAGGAGG GAGAGAGATG TACTTTTTAA    2280
ATCATGTTCC CCCTAAACAT GGCTGTTAAC CCACTGCATG CAGAAACTTG GATGTCACTG    2340
CCTGACATTC ACTTCCAGAG AGGACCTATC CCAAATGTGG AATTGACTGC CTATGCCAAG    2400
TCCCTGGAAA AGGAGCTTCA GTATTGTGGG GCTCATAAAA CATGAATCAA GCAATCCAGC    2460
CTCATGGGAA GTCCTGGCAC AGTTTTTGTA AAGCCCTTGC ACAGCTGGAG AAATGGCATC    2520
ATTATAAGCT ATGAGTTGAA ATGTTCTGTC AAATGTGTCT CACATCTACA CGTGGCTTGG    2580
AGGCTTTTAT GGGGCCCTGT CCAGGTAGAA AAGAAATGGT ATGTAGAGCT TAGATTTCCC    2640
TATTGTGACA GAGCCATGGT GTGTTTGTAA TAATAAAACC AAAGAAACAT A              2691
```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 683 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens
(F) TISSUE TYPE: LUNG
(G) CELL TYPE: ADENOCARCINOMA
(H) CELL LINE: A549

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met Ala Leu Phe Val Arg Leu Leu Ala Leu Ala Leu Ala Leu Ala Leu
1               5                  10                  15

Gly Pro Ala Ala Thr Leu Ala Gly Pro Ala Lys Ser Pro Tyr Gln Leu
            20                  25                  30

Val Leu Gln His Ser Arg Leu Arg Gly Arg Gln His Gly Pro Asn Val
        35                  40                  45

    50                  55                  60

Cys Lys Gln Trp Tyr Gln Arg Lys Ile Cys Gly Lys Ser Thr Val Ile
65                  70                  75                  80

Ser Tyr Glu Cys Cys Pro Gly Tyr Glu Lys Val Pro Gly Glu Lys Gly
                85                  90                  95

Cys Pro Ala Ala Leu Pro Leu Ser Asn Leu Tyr Glu Thr Leu Gly Val
            100                 105                 110
```

```
Val Gly Ser Thr Thr Thr Gln Leu Tyr Thr Asp Arg Thr Glu Lys Leu
        115                 120                 125

Arg Pro Glu Met Glu Gly Pro Gly Ser Phe Thr Ile Phe Ala Pro Ser
    130                 135                 140

Asn Glu Ala Trp Ala Ser Leu Pro Ala Glu Val Leu Asp Ser Leu Val
145                 150                 155                 160

Ser Asn Val Asn Ile Glu Leu Leu Asn Ala Leu Arg Tyr His Met Val
                165                 170                 175
Cys Ala Val Gln Lys Val Ile Gly Thr Asn Arg Lys Tyr Phe Thr Asn

Gly Arg Arg Val Leu Thr Asp Glu Leu Lys His Gly Met Thr Leu Thr
            180                 185                 190

Ser Met Tyr Gln Asn Ser Asn Ile Gln Ile His His Tyr Pro Asn Gly
        195                 200                 205

Ile Val Thr Val Asn Cys Ala Arg Leu Leu Lys Ala Asp His His Ala
    210                 215                 220

Thr Asn Gly Val Val His Leu Ile Asp Lys Val Ile Ser Thr Ile Thr
225                 230                 235                 240

Asn Asn Ile Gln Gln Ile Ile Glu Ile Glu Asp Thr Phe Glu Thr Leu
                245                 250                 255

Arg Ala Ala Val Ala Ala Ser Gly Leu Asn Thr Met Leu Glu Gly Asn
            260                 265                 270

Gly Gln Tyr Thr Leu Leu Ala Pro Thr Asn Glu Ala Phe Glu Lys Ile
        275                 280                 285

Pro Ser Glu Thr Leu Asn Arg Ile Leu Gly Asp Pro Glu Ala Leu Arg
    290                 295                 300

Asp Leu Leu Asn Asn His Ile Leu Lys Ser Ala Met Cys Ala Glu Ala
305                 310                 315                 320

Ile Val Ala Gly Leu Ser Val Glu Thr Leu Glu Gly Thr Thr Leu Glu
                325                 330                 335

Val Gly Cys Ser Gly Asp Met Leu Thr Ile Asn Gly Lys Ala Ile Ile
            340                 345                 350

Ser Asn Lys Asp Ile Leu Ala Thr Asn Gly Val Ile His Tyr Ile Asp
        355                 360                 365

Glu Leu Leu Ile Pro Asp Ser Ala Lys Thr Leu Phe Glu Leu Ala Ala
    370                 375                 380

Glu Ser Asp Val Ser Thr Ala Ile Asp Leu Phe Arg Gln Ala Gly Leu
385                 390                 395                 400

Gly Asn His Leu Ser Gly Ser Glu Arg Leu Thr Leu Leu Ala Pro Leu
                405                 410                 415

Asn Ser Val Phe Lys Asp Gly Thr Pro Pro Ile Asp Ala His Thr Arg
            420                 425                 430

Asn Leu Leu Arg Asn His Ile Ile Lys Asp Gln Leu Ala Ser Lys Tyr
        435                 440                 445

Leu Tyr His Gly Gln Thr Leu Glu Thr Leu Gly Gly Lys Lys Leu Arg
    450                 455                 460
```

```
Val Phe Val Tyr Arg Asn Ser Leu Cys Ile Glu Asn Ser Cys Ile Ala
465                 470                 475                 480

Ala His Asp Lys Arg Gly Arg Tyr Gly Thr Leu Phe Thr Met Asp Arg
                485                 490                 495

Val Leu Thr Pro Pro Met Gly Thr Val Met Asp Val Leu Lys Gly Asp
            500                 505                 510

Asn Arg Phe Ser Met Leu Val Ala Ala Ile Gln Ser Ala Gly Leu Thr
        515                 520                 525

Glu Thr Leu Asn Arg Glu Gly Val Tyr Thr Val Phe Ala Pro Thr Asn
    530                 535                 540

Glu Ala Phe Arg Ala Leu Pro Pro Arg Glu Arg Ser Arg Leu Leu Gly
545                 550                 555                 560

Asp Ala Lys Glu Leu Ala Asn Ile Leu Lys Tyr His Ile Gly Asp Glu
                565                 570                 575

Ile Leu Val Ser Gly Gly Ile Gly Ala Leu Val Arg Leu Lys Ser Leu
            580                 585                 590

Gln Gly Asp Lys Leu Glu Val Ser Leu Lys Asn Asn Val Val Ser Val
        595                 600                 605

Asn Lys Glu Pro Val Ala Glu Pro Asp Ile Met Ala Thr Asn Gly Val
    610                 615                 620

Val His Val Ile Thr Asn Val Leu Gln Pro Pro Ala Asn Arg Pro Gln
625                 630                 635                 640

Glu Arg Gly Asp Glu Leu Ala Asp Ser Ala Leu Glu Ile Phe Lys Gln
                645                 650                 655

Ala Ser Ala Phe Ser Arg Ala Ser Gln Arg Ser Val Arg Leu Ala Pro
            660                 665                 670

Val Tyr Gln Lys Leu Leu Glu Arg Met Lys His
        675                 680
```

Claims

1. A substantially pure protein comprising a protein having a sequence of about 683 amino acid residues in length and substantially corresponding to Sequence I.D. 2, wherein said protein is induced by contacting mammalian cells with transforming growth factor beta to growth arrest said cells.

2. The protein according to Claim 1, wherein said transforming growth factor beta is selected from the group consisting of TGF-β1, TGF-β2, TGF-β3, a TGF-β1/β2 hybrid molecule and fragments thereof.

3. The protein according to Claim 1, wherein said protein is βIG-H3.

4. The protein according to Claim 1, wherein said protein contains four homologous repeating regions.

5. The protein according to Claim 1, wherein said mammalian cells are human cells.

6. The protein according to Claim 1, wherein said human cells are selected from the group consisting of lung adenocarcinoma cells, embryonic palatal mesenchymal cells and prostatic adenocarcinoma cells.

7. βIG-H3, a substantially pure protein comprising an amino acid residue sequence of about 683 amino acid residues substantially corresponding to Sequence I.D. 2 and FIGURE 5, wherein said protein contains an

Arg-Gly-Asp sequence in the carboxy terminal amino acids corresponding to amino acid residues 642-644 in FIGURE 5.

8. βIG-H3 according to Claim 7, wherein said protein contains four homologous repeating regions as depicted in FIGURE 6.

9. βIG-H3 according to Claim 8, wherein said repeating regions have a homology of at least 16% with each other.

10. A substantially pure nucleotide sequence encoding a gene whose expression is induced by contacting mammalian cells with transforming growth factor beta, comprising a nucleotide sequence substantially corresponding to Sequence I.D. 1 and FIGURE 5.

11. The nucleotide sequence according to Claim 10, wherein said transforming growth factor beta induces the production of a 3.4 kilobase RNA transcript from said gene.

12. The nucleotide sequence according to Claim 10, wherein said transforming growth factor beta is selected from the group consisting of TGF-β1, TGF-β2, TGF-β3, a TGF-β1/β2 hybrid molecule and fragments thereof.

13. The nucleotide sequence according to Claim 10, wherein said gene encodes the expression of βIG-H3.

14. A process for the production of a protein according to any one of Claims 1 to 9, comprising the steps of:
i) inserting the nucleotide sequence of any one of Claims 10 to 13 into an expression system;
ii) inducing the expression system to express the nucleotide sequence to form a protein product; and
iii) isolating the protein product.

15. A process for identifying a protein whose expression is induced by TGF-β comprising the steps of:
i) growing a cell in the presence of TGF-β;
ii) constructing a cDNA library from the cell;
iii) comparing the cDNA library with another cDNA library constructed from a cell grown in the absence of TGF-β and identifying the TGF-β-specific clones; and
iv) further characterising the TGF-β-specific clones to identify the proteins thereby encoded.



Figure 1



Figure 2



Figure 3



Figure 4

```
                -47 GCTTGCCCGTCGGTCGCTAGCTCGCTCGGTGCGCGTCGTCCCGCTCC     -1

                                                  10
Met Ala Leu Phe Val Arg Leu Leu Ala Leu Ala Leu Ala Leu Ala Leu
ATG GCG CTC TTC GTG CGG CTG CTG GCT CTC GCC CTG GCT CTG GCC CTG      48

                20
Gly Pro Ala Ala Thr Leu Ala Gly Pro Ala Lys Ser Pro Tyr Gln Leu
GGC CCC GCC GCG ACC CTG GCG GGT CCC GCC AAG TCG CCC TAC CAG CTG      96

          35                                                45
Val Leu Gln His Ser Arg Leu Arg Gly Arg Gln His Gly Pro Asn Val
GTG CTG CAG CAC AGC AGG CTC CGG GGC CGC CAG CAC GGC CCC AAC GTG     144

                                                  60
Cys Ala Val Gln Lys Val Ile Gly Thr Asn Arg Lys Tyr Phe Thr Asn
TGT GCT GTG CAG AAG GTT ATT GGC ACT AAT AGG AAG TAC TTC ACC AAC     192

                        70
Cys Lys Gln Trp Tyr Gln Arg Lys Ile Cys Gly Lys Ser Thr Val Ile
TGC AAG CAG TGG TAC CAA AGG AAA ATC TGT GGC AAA TCA ACA GTC ATC     240

                    85                                        95
Ser Tyr Glu Cys Cys Pro Gly Tyr Glu Lys Val Pro Gly Glu Lys Gly
AGC TAC GAG TGC TGT CCT GGA TAT GAA AAG GTC CCT GGG GAG AAG GGC     288

                                                      110
Cys Pro Ala Ala Leu Pro Leu Ser Asn Leu Tyr Glu Thr Leu Gly Val
TGT CCA GCA GCC CTA CCA CTC TCA AAC CTT TAC GAG ACC CTG GGA GTC     336

                            120
Val Gly Ser Thr Thr Thr Gln Leu Tyr Thr Asp Arg Thr Glu Lys Leu
GTT GGA TCC ACC ACC ACT CAG CTG TAC ACG GAC CGC ACG GAG AAG CTG     384

                        135                 REPEAT 1
Arg Pro Glu Met Glu Gly Pro Gly Ser Phe Thr Ile Phe Ala Pro Ser
AGG CCT GAG ATG GAG GGG CCC GGC AGC TTC ACC ATC TTC GCC CCT AGC     432

145                                                           160
Asn Glu Ala Trp Ala Ser Leu Pro Ala Glu Val Leu Asp Ser Leu Val
AAC GAG GCC TGG GCC TCC TTG CCA GCT GAA GTG CTG GAC TCC CTG GTC     480

                                170
Ser Asn Val Asn Ile Glu Leu Leu Asn Ala Leu Arg Tyr His Met Val
AGC AAT GTC AAC ATT GAG CTG CTC AAT GCC CTC CGC TAC CAT ATG GTG     528

                            185
Gly Arg Arg Val Leu Thr Asp Glu Leu Lys His Gly Met Thr Leu Thr
GGC AGG CGA GTC CTG ACT GAT GAG CTG AAA CAC GGC ATG ACC CTC ACC     576

          195
Ser Met Tyr Gln Asn Ser Asn Ile Gln Ile His His Tyr Pro Asn Gly
TCT ATG TAC CAG AAT TCC AAC ATC CAG ATC CAC CAC TAT CCT AAT GGG     624
```

Figure 5 (i)

```
    210                                                 220
Ile Val Thr Val Asn Cys Ala Arg Leu Leu Lys Ala Asp His His Ala
ATT GTA ACT GTG AAC TGT GCC CGG CTC CTG AAA GCC GAC CAC CAT GCA     672

                                                    235
Thr Asn Gly Val Val His Leu Ile Asp Lys Val Ile Ser Thr Ile Thr
ACC AAC GGG GTG GTG CAC CTC ATC GAT AAG GTC ATC TCC ACC ATC ACC     720

                    245
Asn Asn Ile Gln Gln Ile Ile Glu Ile Glu Asp Thr Phe Glu Thr Leu
AAC AAC ATC CAG CAG ATC ATT GAG ATC GAG GAC ACC TTT GAG ACC CTT     768

            260                                         270
Arg Ala Ala Val Ala Ala Ser Gly Leu Asn Thr Met Leu Glu Gly Asn
CGG GCT GCT GTG GCT GCA TCA GGG CTC AAC ACG ATG CTT GAA GGT AAC     816

          ____      REPEAT 2                            285
Gly Gln | Tyr Thr Leu Leu Ala Pro Thr Asn Glu Ala Phe Glu Lys Ile
GGC CAG | TAC ACG CTT TTG GCC CCG ACC AAT GAG GCC TTC GAG AAG ATC     864
        |

                        295
Pro Ser Glu Thr Leu Asn Arg Ile Leu Gly Asp Pro Glu Ala Leu Arg
CCT AGT GAG ACT TTG AAC CGT ATC CTG GGC GAC CCA GAA GCC CTG AGA     912

                310                                         320
Asp Leu Leu Asn Asn His Ile Leu Lys Ser Ala Met Cys Ala Glu Ala
GAC CTG CTG AAC AAC CAC ATC TTG AAG TCA GCT ATG TGT GCT GAA GCC     960

                                                        335
Ile Val Ala Gly Leu Ser Val Glu Thr Leu Glu Gly Thr Thr Leu Glu
ATC GTT GCG GGG CTG TCT GTA GAG ACC CTG GAG GGC ACG ACA CTG GAG    1008

                            345
Val Gly Cys Ser Gly Asp Met Leu Thr Ile Asn Gly Lys Ala Ile Ile
GTG GGC TGC AGC GGG GAC ATG CTC ACT ATC AAC GGG AAG GCG ATC ATC    1056

                        360
Ser Asn Lys Asp Ile Leu Ala Thr Asn Gly Val Ile His Tyr Ile Asp
TCC AAT AAA GAC ATC CTA GCC ACC AAC GGG GTG ATC CAC TAC ATT GAT    1104

    370
Glu Leu Leu Ile Pro Asp Ser Ala Lys Thr Leu Phe Glu Leu Ala Ala
GAG CTA CTC ATC CCA GAC TCA GCC AAG ACA CTA TTT GAA TTG GCT GCA    1152

385                                                 395
Glu Ser Asp Val Ser Thr Ala Ile Asp Leu Phe Arg Gln Ala Gly Leu
GAG TCT GAT GTG TCC ACA GCC ATT GAC CTT TTC AGA CAA GCC GGC CTC    1200

                                    410     ____    REPEAT 3
Gly Asn His Leu Ser Gly Ser Glu Arg Leu | Thr Leu Leu Ala Pro Leu
GGC AAT CAT CTC TCT GGA AGT GAG CGG TTG | ACC CTC CTG GCT CCC CTG    1248
                                       |
```

Figure 5 (ii)

```
                420
Asn Ser Val Phe Lys Asp Gly Thr Pro Pro Ile Asp Ala His Thr Arg
AAT TCT GTA TTC AAA GAT GGA ACC CCT CCA ATT GAT GCC CAT ACA AGG   1296

        435                                     445
Asn Leu Leu Arg Asn His Ile Ile Lys Asp Gln Leu Ala Ser Lys Tyr
AAT TTG CTT CGG AAC CAC ATA ATT AAA GAC CAG CTG GCC TCT AAG TAT   1344

                                            460
Leu Tyr His Gly Gln Thr Leu Glu Thr Leu Gly Gly Lys Lys Leu Arg
CTG TAC CAT GGA CAG ACC CTG GAA ACT CTG GGC GGC AAA AAA CTG AGA   1392

                    470
Val Phe Val Tyr Arg Asn Ser Leu Cys Ile Glu Asn Ser Cys Ile Ala
GTT TTT GTT TAT CGT AAT AGC CTC TGC ATT GAG AAC AGC TGC ATC GCG   1440

                485                                 495
Ala His Asp Lys Arg Gly Arg Tyr Gly Thr Leu Phe Thr Met Asp Arg
GCC CAC GAC AAG AGG GGG AGG TAC GGG ACC CTG TTC ACG ATG GAC CGG   1488

                                                510
Val Leu Thr Pro Pro Met Gly Thr Val Met Asp Val Leu Lys Gly Asp
GTG CTG ACC CCC CCA ATG GGG ACT GTC ATG GAT GTC CTG AAG GGA GAC   1536

                            520
Asn Arg Phe Ser Met Leu Val Ala Ala Ile Gln Ser Ala Gly Leu Thr
AAT CGC TTT AGC ATG CTG GTA GCT GCC ATC CAG TCT GCA GGA CTG ACG   1584

                        535                 REPEAT 4
Glu Thr Leu Asn Arg Glu Gly Val Tyr Thr Val Phe Ala Pro Thr Asn
GAG ACC CTC AAC CGG GAA GGA GTC TAC ACA GTC TTT GCT CCC ACA AAT   1632

545                                                         560
Glu Ala Phe Arg Ala Leu Pro Pro Arg Glu Arg Ser Arg Leu Leu Gly
GAA GCC TTC CGA GCC CTG CCA CCA AGA GAA CGG AGC AGA CTC TTG GGA   1680

                                    570
Asp Ala Lys Glu Leu Ala Asn Ile Leu Lys Tyr His Ile Gly Asp Glu
GAT GCC AAG GAA CTT GCC AAC ATC CTG AAA TAC CAC ATT GGT GAT GAA   1728

                                585
Ile Leu Val Ser Gly Gly Ile Gly Ala Leu Val Arg Leu Lys Ser Leu
ATC CTG GTT AGC GGA GGC ATC GGG GCC CTG GTG CGG CTA AAG TCT CTC   1776

        595
Gln Gly Asp Lys Leu Glu Val Ser Leu Lys Asn Asn Val Val Ser Val
CAA GGT GAC AAG CTG GAA GTC AGC TTG AAA AAC AAT GTG GTG AGT GTC   1824

    610                                     620
Asn Lys Glu Pro Val Ala Glu Pro Asp Ile Met Ala Thr Asn Gly Val
AAC AAG GAG CCT GTT GCC GAG CCT GAC ATC ATG GCC ACA AAT GGC GTG   1872
```

Figure 5 (iii)

```
                                                  635
Val His Val Ile Thr Asn Val Leu Gln Pro Pro Ala Asn Arg Pro Gln
GTC CAT GTC ATC ACC AAT GTT CTG CAG CCT CCA GCC AAC AGA CCT CAG   1920

                645
Glu Arg Gly Asp Glu Leu Ala Asp Ser Ala Leu Glu Ile Phe Lys Gln
GAA AGA GGG GAT GAA CTT GCA GAC TCT GCG CTT GAG ATC TTC AAA CAA   1968

            660                                         670
Ala Ser Ala Phe Ser Arg Ala Ser Gln Arg Ser Val Arg Leu Ala Pro
GCA TCA GCG TTT TCC AGG GCT TCC CAG AGG TCT GTG CGA CTA GCC CCT   2016

Val Tyr Gln Lys Leu Leu Glu Arg Met Lys His ***
GTC TAT CAA AAG TTA TTA GAG AGG ATG AAG CAT TAG CTTGAAGCACTACAG   2067

GAGGAATGCACCACGGCAGCTCTCCGCCAATTTCTCTCAGATTTCCACAGAGACTGTTTGAATG  2131

TTTTCAAAACCAAGTATCACACTTTAATGTACATGGGCCGCACCATAATGAGATGTGAGCCTTG  2195

TGCATGTGGGGGAGGAGGGAGAGAGATGTACTTTTTAAATCATGTTCCCCCTAAACATGGCTGT  2259

TAACCCACTGCATGCAGAAACTTGGATGTCACTGCCTGACATTCACTTCCAGAGAGGACCTATC  2323

CCAAATGTGGAATTGACTGCCTATGCCAAGTCCCTGGAAAAGGAGCTTCAGTATTGTGGGGCTC  2387

ATAAAACATGAATCAAGCAATCCAGCCTCATGGGAAGTCCTGGCACAGTTTTTGTAAAGCCCTT  2451

GCACAGCTGGAGAAATGGCATCATTATAAGCTATGAGTTGAAATGTTCTGTCAAATGTGTCTCA  2515

CATCTACACGTGGCTTGGAGGCTTTTATGGGGCCCTGTCCAGGTAGAAAAGAAATGGTATGTAG  2579

AGCTTAGATTTCCCTATTGTGACAGAGCCATGGTGTGTTTGTAATAATAAAACCAAAGAAACAT  2643

A                                                                  2644
```

Figure 5 (iv)


A
aaℓ
βIG-H3ℓ1 139
βIG-H3ℓ2 276
βIG-H3ℓ3 411
βIG-H3ℓ4 538
DrF-3 358
GrF-3 367
Mpb70 97
aaℓ
βIG-H3ℓ1 275.
βIG-H3ℓ2 410.
βIG-H3ℓ3 537.
βIG-H3ℓ4 670
DrF-3 503.
GrF-3 510
Mpb70 193.
B
aaℓ
βIG-H3ℓ2 276
βIG-H3ℓ4 538
βIG-H3ℓ1 139
βIG-H3ℓ3 411
aaℓ
βIG-H3ℓ2 410
βIG-H3ℓ4 APYYQKLLERMKH-cooh 683
βIG-H3ℓ1 275
βIG-H3ℓ3 537

Figure 6

European Patent Office

EUROPEAN SEARCH REPORT

Application Number

EP 93 30 0809

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
A	Dialog Information Services, File 5: Biosis 1969 to the present, Accession No. 8563529, A Brunner et al.: "Identification of a gene family regulated by transforming growth factor-beta" & DNA Cell Biology, vol. 10, no. 4 (1991), pages 293-300		C12N15/12 C07K15/00
A	THE EMBO JOURNAL vol. 7, no. 10, 1988, IRL PRESS LTD., OXFORD, UK pages 2977 - 2981 C.A. PEARSON ET AL. 'Tenascin: cDNA cloning and induction by TGF-beta'		
D,A	CELL vol. 53, 1988, USA pages 577 - 587 K. ZINN ET AL. 'Sequence analysis and neuronal expression of fasciclin I in grasshopper and Drosophila'		TECHNICAL FIELDS SEARCHED (Int. Cl.5)
A	MOLECULAR AND CELLULAR BIOLOGY vol. 11, no. 10, 1991, NEW YORK, USA pages 5338 - 5345 B. KALLIN ET AL. 'Cloning of a growth arrest-specific and transforming growth factor-beta-regulated gene, TI 1, from an epithelial cell line'		C12N C07K
P,X	Dialog Information Services, File 5: Biosis 1969 to the present, Accession No. 10004348, J. Skonier et al.: "cDNA cloning and sequence analysis of beta-IG-H3 a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta" & DNA Cell Biology, Vol. 11, no. 7 (1992), pages 511-522	1-15	

The present search report has been drawn up for all claims

Place of search	Date of completion of the search	Examiner
MUNICH	13 MAY 1993	YEATS S.

CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A : technological background
O : non-written disclosure
P : intermediate document

T : theory or principle underlying the invention
E : earlier patent document, but published on, or after the filing date
D : document cited in the application
L : document cited for other reasons

& : member of the same patent family, corresponding document

EPO FORM 1503 03.82 (P0401)